A treatment for retinal vein occlusion (RVO) — one of the most common blinding conditions in the United States — may lead to long-term vision improvement, according to new research published by a Penn State College of Medicine researcher and colleagues.
Without treatment, central retinal vein occlusion, the most severe type of retinal vein occlusion, often leads to significant and permanent vision loss. The disease can cause obstruction of the veins carrying blood away from the retina, the light-sensitive tissue at the back of the eye. This can lead to macular edema, where fluid becomes trapped within and under the retina, leading to rapid and severe loss of visual acuity. Injections of anti-vascular endothelial growth factor (anti-VEGF) drugs may help control blood vessel leakage and swelling in the retina and are considered the most effective treatment.
A report on five-year outcomes of the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2), was published in the American Journal of Ophthalmology. Dr. Ingrid Scott, Jack and Nancy Turner Professor of Ophthalmology and professor of public health sciences, received more than $11 million from the National Eye Institute, a part of the National Institutes of Health, to lead the study.














